Gaining Respect, New Methodologies, And Life After NICE: An Interview With Michael Rawlins
Executive Summary
Sir Michael Rawlins talks about his views on EuroNICE, PCORI and the future of health technology assessment as he prepares to step down after nearly 14 years as chairman of the U.K.'s cost regulator, the National Institute for Health and Clinical Excellence.
You may also be interested in...
Value-Based Pricing Could Boost Global Applicability Of NICE Appraisals
Value-based pricing will start in the U.K. in January 2014 for newly launched products, with prices taking into account innovation and societal benefit as well as NICE's usual clinical and cost-effectiveness analysis, U.K. Health Secretary Andrew Lansley tells NICE's annual conference.
Pipeline Watch: Phase III Starts In CLL, Urothelial Cancer, And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
ITM Charts A Path From Radionuclides To Radiotherapeutics And Attracts Financing
Interview: Germany’s ITM is executing on its plan to develop targeted radionuclide-based therapies with its lead lutetium-177 product in Phase III trials supported by a just closed $109m financing.